AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $318.59 million. The enterprise value is $134.33 million.
Important Dates
The last earnings date was Tuesday, November 5, 2024, before market open.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 98.94 million shares outstanding. The number of shares has increased by 14.86% in one year.
| Current Share Class | 98.94M |
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | +14.86% |
| Shares Change (QoQ) | +1.31% |
| Owned by Insiders (%) | 3.06% |
| Owned by Institutions (%) | 9.07% |
| Float | 39.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.38 |
| Forward PS | 559.90 |
| PB Ratio | 2.08 |
| P/TBV Ratio | 3.36 |
| P/FCF Ratio | 6.52 |
| P/OCF Ratio | 6.14 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.76 |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.86 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.07 |
| Interest Coverage | -289.16 |
Financial Efficiency
Return on equity (ROE) is -31.16% and return on invested capital (ROIC) is -17.84%.
| Return on Equity (ROE) | -31.16% |
| Return on Assets (ROA) | -12.04% |
| Return on Capital (ROIC) | -17.84% |
| Revenue Per Employee | $301,276 |
| Profits Per Employee | -$293,114 |
| Employee Count | 161 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $1,184 in taxes.
| Income Tax | 1,184 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.59% in the last 52 weeks. The beta is 1.26, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -5.59% |
| 50-Day Moving Average | 3.28 |
| 200-Day Moving Average | 3.37 |
| Relative Strength Index (RSI) | 48.26 |
| Average Volume (20 Days) | 140,193 |
Short Selling Information
| Short Interest | 1.05M |
| Short Previous Month | 984,461 |
| Short % of Shares Out | 1.99% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.10 |
Income Statement
In the last 12 months, AC Immune had revenue of $48.51 million and -$47.19 million in losses. Loss per share was -$0.49.
| Revenue | 48.51M |
| Gross Profit | -24.22M |
| Operating Income | -44.16M |
| Pretax Income | -69.76M |
| Net Income | -47.19M |
| EBITDA | -42.33M |
| EBIT | -44.16M |
| Loss Per Share | -$0.49 |
Full Income StatementBalance Sheet
The company has $186.92 million in cash and $3.65 million in debt, giving a net cash position of $183.27 million or $1.85 per share.
| Cash & Cash Equivalents | 186.92M |
| Total Debt | 3.65M |
| Net Cash | 183.27M |
| Net Cash Per Share | $1.85 |
| Equity (Book Value) | 154.09M |
| Book Value Per Share | 1.54 |
| Working Capital | 102.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $51.75 million and capital expenditures -$771,863, giving a free cash flow of $48.68 million.
| Operating Cash Flow | 51.75M |
| Capital Expenditures | -771,863 |
| Free Cash Flow | 48.68M |
| FCF Per Share | $0.49 |
Full Cash Flow StatementMargins
Gross margin is -49.93%, with operating and profit margins of -91.04% and -97.29%.
| Gross Margin | -49.93% |
| Operating Margin | -91.04% |
| Pretax Margin | -97.29% |
| Profit Margin | -97.29% |
| EBITDA Margin | -87.27% |
| EBIT Margin | -91.04% |
| FCF Margin | 286.56% |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.86% |
| Shareholder Yield | -14.86% |
| Earnings Yield | -14.86% |
| FCF Yield | 15.33% |
Analyst Forecast
The average price target for AC Immune is $12.00, which is 272.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 272.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 69.68% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -0.45 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.45 |
| Piotroski F-Score | 4 |